...
首页> 外文期刊>American Journal of Translational Research >Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy
【24h】

Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy

机译:Formononetin通过抑制自噬改善紫杉醇抗性三重阴性乳腺癌的耐药性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Characterized by autophagy-associated protein disorders, autophagy participates in Taxol resistance in triple negative breast cancer (TNBC). As an evolutionarily conserved serine/threonine protein kinase with complex signaling pathway, mammalian target of rapamycin (mTOR) can regulate various cellular functions by phosphorylation of its downstream target proteins after activation. A large number of references have demonstrated that mTOR signaling pathway is related to autophagy and apoptosis. Formononetin (FMNT) has anticancer properties against breast, prostate and colon cancers. This study aimed to explore the regulatory effect of FMNT/miR-199a-3p/mTOR pathway on Taxol resistance and autophagy in breast cancer (BC). MiR-199a-3p, mTOR, LC3 and other autophagy related proteins were detected in Taxol sensitive and Taxol resistant TNBC cell lines, which were MDA-MB-231 and MDA-MB-231/Taxol, respectively. Cell viability and toxicity were determined by CCK-8 and MTT assay, respectively. The therapeutic effect of FMNT was evaluated in xenotransplantation model of nude mice. MiR-199a-3p was more highly expressed in MDA-MB-231/Taxol than in MDA-MB-231, while mTOR and p-mTOR decreased in MDA-MB-231/Taxol in comparison with MDA-MB-231, and autophagy activation and drug resistance were enhanced. In MDA-MB-231/Taxol cell line, the role of FMNT was verified to inhibit high miR-199a-3p expression. In addition, the combination therapy of FMNT and Taxol was found to be more effective in inhibiting autophagy and drug resistance. Moreover, mTOR was the target of miR-199a-3p, which was confirmed by dual luciferase reporter (DLR) gene assay. Oral administration of FMNT reduced tumor volume after MDA-MB-231/Taxol injection in vivo. Moreover, oral administration of FMNT and Taxol suppressed autophagy and Taxol resistance by restoring mTOR protein level to that of the parent MDA-MB-231, suggesting that miR-199a-3p can severe as a new target to overcome Taxol resistance in TNBC.
机译:以自噬相关的蛋白质疾病为特征,自噬参与三重阴性乳腺癌(TNBC)中的紫杉醇抗性。作为具有复杂信号通路的进化保守的丝氨酸/苏氨酸蛋白激酶,哺乳动物雷帕霉素(MTOR)靶标可以通过激活后通过磷酸化调节各种细胞功能。大量参考文献表明,MTOR信号传导途径与自噬和凋亡有关。 FormononeTin(FMNT)对乳腺癌,前列腺和结肠癌的抗癌性能。本研究旨在探讨FMNT / MIR-19A-3P / MTOR途径对乳腺癌(BC)紫杉醇抗性和自噬的调节作用。在紫杉醇敏感性和紫杉醇抗性TNBC细胞系中检测miR-199A-3P,MTOR,LC3和其他自噬蛋白,分别是MDA-MB-231和MDA-MB-231 /紫杉醇。通过CCK-8和MTT测定法测定细胞活力和毒性。裸鼠的Xenotroansplantation模型评价FMNT的治疗效果。 miR-199A-3P在MDA-MB-231 /紫杉醇中更高度表达,而不是MDA-MB-231,而MDA-MB-231 /紫杉醇的MTOR和P-MTOR与MDA-MB-231相比减少,提高了自噬激活和耐药性。在MDA-MB-231 /紫杉醇细胞系中,验证FMNT的作用以抑制高miR-199A-3P表达。此外,发现FMNT和紫杉醇的组合治疗在抑制自噬和耐药性方面更有效。此外,MTOR是MIR-199A-3P的靶标,其通过双荧光素酶报告(DLR)基因测定来证实。在体内MDA-MB-231 /紫杉醇注射后的口服施​​用FMNT降低肿瘤体积。此外,通过将MTOR蛋白水平恢复到母体MDA-MB-231的MTOR蛋白水平抑制FMNT和紫杉醇的口服给予自噬和紫杉醇抗性,表明MIR-199A-3P可以严重作为克服TNBC紫杉醇抗性的新靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号